News
CAI
19.29
+0.84%
0.16
CARIS LIFE SCIENCES INC - INITIAL TERM FACILITY MATURES IN APRIL 2031; DELAYED DRAW AVAILABLE THROUGH AUGUST 2027 - SEC FILING
Reuters · 3d ago
Caris Life Sciences signs $400 million term loan with Blue Owl, Blackstone lenders
Reuters · 3d ago
Caris Life Sciences launches Caris ChromoSeq tumor profiling assay
TipRanks · 3d ago
Caris Life Sciences Launches ChromoSeq, Ultra-Deep Genome And Transcriptome Test To Streamline Diagnosis Of Myeloid Malignancies
Benzinga · 3d ago
CARIS LIFE SCIENCES INC - LAUNCHES CARIS CHROMOSEQ FOR MYELOID MALIGNANCIES
Reuters · 3d ago
Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies
PR Newswire · 3d ago
Why Is Caris Life Sciences Stock Gaining Wednesday?
Benzinga · 4d ago
Evercore ISI Sticks to Their Buy Rating for Caris Life Sciences, Inc. (CAI)
TipRanks · 4d ago
Caris Life Sciences initiated with a Buy at Goldman Sachs
TipRanks · 4d ago
Caris Life Sciences announces finalized Achieve 1 Study results
TipRanks · 5d ago
Caris Life Sciences Finalizes Achieve 1 Study; Results Demonstrate The Superiority Of Whole Genome Sequencing Compared To Methylation-Based Approaches
Benzinga · 5d ago
Caris finalizes Achieve 1 study, posts 56.8% Stage I sensitivity for Detect test
Reuters · 5d ago
Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect
PR Newswire · 5d ago
Weekly Report: what happened at CAI last week (0323-0327)?
Weekly Report · 6d ago
Caris Life Sciences adds two AI signatures predicting brain metastases risk in breast and lung cancer; study progresses on 12,994 NSCLC cases and 3,371 breast cancer cases
Reuters · 03/26 12:30
Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer
PR Newswire · 03/26 12:30
Caris Life Sciences announces six oncology studies for AACR 2026; research focus expands across breast, prostate, lung, and colorectal cancers
Reuters · 03/25 12:31
Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026
PR Newswire · 03/25 12:30
Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month
PR Newswire · 03/24 12:30
Weekly Report: what happened at CAI last week (0316-0320)?
Weekly Report · 03/23 09:51
More
Webull provides a variety of real-time CAI stock news. You can receive the latest news about Caris Life Sciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CAI
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.